A cost-effectiveness analysis of Gd-EOB-DTPA contrast-enhanced magnetic resonance imaging versus ultrasound in hepatocellular carcinoma screening
10.3969/j.issn.1001-5256.2018.09.018
- VernacularTitle:钆塞酸二钠增强磁共振成像与超声在肝细胞癌筛查中的成本效益分析
- Author:
Qiping CHEN
1
;
Su LIN
;
Zhenshan SHI
Author Information
1. Liver Research Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China
- Publication Type:Research Article
- Keywords:
carcinoma, hepatocellular;
magnetic resonance imaging;
ultrasonography;
early diagnosis;
cost-benefit analysis
- From:
Journal of Clinical Hepatology
2018;34(9):1917-1920
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the cost-effectiveness ratio of Gd-EOB-DTPA contrast-enhanced magnetic resonance imaging (EMRI) versus ultrasound in liver cancer screening for the high-risk population. MethodsThe TreeAge Pro 2011 software was used to establish a decision-tree model. A mathematical model was used to simulate the costs and benefits of EMRI or ultrasound screening every 6 months in patients with liver cirrhosis, and the cost-effectiveness ratios under different screening models were calculated. ResultsThe EMRI group had a mean cost of liver cancer screening of 2050.2 RMB each person each time and mean benefits of 0.11 YLG, while the ultrasound group had a mean cost of 262.6 RMB and mean benefits of 0.02 YLG. When the incidence rate of liver cancer was 17.8%, the EMRI group had a similar cost-effectiveness ratio as the ultrasound group, and the cost of 1 YLG was 11445 RMB; EMRI tended to have a lower cost and a better effect in screening with the increase in the incidence rate of liver cancer. The cost-effectiveness ratio of EMRI gradually decreased with the reduction in its price, and its effect in screening gradually increased with the reduction in price. ConclusionThe cost-effectiveness of liver cancer screening is closely related to the incidence rate of liver cancer and the price of screening. EMRI has a good cost-effectiveness ratio in screening when the risk of liver cancer is higher than 17.8%.
